## SYNTHESIS OF 7-CHLORO-5-(4-CHLOROPHENYL)-1-METHYL-1,3-DIHYDRO-1,4-BENZODIAZEPIN-2-ONE


# Zdeněk VEJDĚLEK, Zdeněk Polívka and Miroslav Protiva

Research Institute for Pharmacy and Biochemistry, 130 60 Prague 3

Received August 10th, 1984


The synthesis of the title compound II was carried out from 5-chloro-3-(4-chlorophenyl)-2,1benzisoxazole (III) by two methods proceeding via new intermediates V and VI. 5-(2-Fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one (VII) was synthesized from 2-amino-2'-fluorobenzophenone via VIII.

In contradistinction of 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one (I) (experimental agent Ro 5-3448) (ref.<sup>1</sup>), which has strong central depressant, anticonvulsant and anxiolytic activity, its position isomer II (the 4-chlorophenyl compound), known under the code number Ro 5-4864, is indeed likewise a ligand for the central and peripheral benzodiazepine binding sites but its pharmacodynamic potency is considerably lower and is partly reverted to the antagonistic one (convulsant action) (ref.<sup>2-5</sup>); in the form of its tritiated analogue, the compound is an excellent tool for localization and characterization of the benzodiazepine receptors<sup>6,7</sup>. The substance was needed in our pharmacological laboratory and, therefore, its synthesis has to be considered. This was described by several methods<sup>8-15</sup> which mostly appeared tedious and little effective. For this reason, we prepared compound II using two further methods, and the description of this work is the main object of this communication.




5-Chloro-3-(4-chlorophenyl)-2,1-benzisoxazole (111) was chosen as the starting compound being easily accessible by reaction of 4-chlorophenylacetonitrile<sup>16</sup> with 4-chloronitrobenzene in methanolic potassium hydroxide under cooling<sup>17</sup>. The

described procedure was modified by substantial reduction of the used amount of potassium hydroxide. For the direct conversion of compound III to 5,4'-dichloro--2-methylaminobenzophenone (IV) (ref.<sup>18</sup>) we used the method, described in<sup>19</sup> for the preparation of the corresponding 4'-dechloroanalogue, consisting in treating compound III with dimethyl sulfate and in the following reduction of the nonisolated quaternary salt with iron and hydrochloric acid in boiling ethanol.



For concluding the synthesis of compound II, two methods were used. In the first one the intermediate IV was acylated with chloroacetyl chloride in benzene in the presence of ice and in a high yield amide V was obtained. Treatment with hexamethylenetetramine in boiling aqueous methanol (method<sup>20,21</sup>) gave the compound II in a yield of 94%. The second procedure used the Podešva's approach<sup>22</sup> (cf. our preceding papers<sup>23-25</sup>): treatment of the intermediate IV with phthalimidoacetyl chloride<sup>26-28</sup> in boiling chloroform resulted in the phthalimide derivative VI which was transformed to compound II by hydrazinolysis in methanol at 60°C. The product II, obtained in a yield of 80%, melted by 6°C higher than described in the literature<sup>8</sup> and its identity was confirmed by analysis and by spectra.



Collection Czechoslovak Chem. Commun. [Vol. 50] [1985]

In a different connection we used Podešva's method<sup>22</sup> in the synthesis of 5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one (VII) (ref.<sup>29</sup>) which is an importanintermediate. 2-Amino-2'-fluorobenzophenone<sup>29</sup> afforded by treatment with phthalimidoacetyl chloride<sup>26-28</sup> in boiling chloroform the phthalimide derivative VIII (was claimed in a patent<sup>30</sup> but not described) which was subjected to hydrazinolysis in aqueous ethanol at 60°C to yield VII (94%).

### EXPERIMENTAL

The melting points of analytical samples were determined in Kofler's block and they are not corrected; the samples were dried *in vacuo* of about 60 Pa over  $P_2O_5$  at 77°C or at room temperature. The UV spectra (in methanol) were recorded with a Unicam SP 8000 spectrophotometer, IR spectra with a Perkin Elmer 298 spectrophotometer and <sup>1</sup>H NMR spectra (mostly in C<sup>2</sup>HCl<sub>3</sub>) with a Tesla BS 487C (80 MHz) spectrometer. The homogeneity of the compounds and composition of the mixtures were checked by thin-layer chromatography on silica gel (Silufol).

5-Chloro-3-(4-chlorophenyl)-2,1-benzisoxazole (III)

A solution of 438 g 85% KOH in 865 ml methanol was stirred and treated at  $17-20^{\circ}$ C with a solution of 99 g 4-chloronitrobenzene and 105 g 4-chlorophenylacetonitrile<sup>16</sup> in 300 ml benzene, added dropwise over 75 min. The mixture was stirred for 3 h at room temperature and poured into a stirred solution of 430 g NH<sub>4</sub>Cl in 3 l water, it was stirred for 1 h and allowed to stand overnight. The precipitated product was filtered, washed with a mixture of benzene and hexane, then with hexane, and dried *in vacuo*; 66·0 g, m.p. 214-215°C. The organic layer of the filtrate was separated, the aqueous layer was extracted with 500 ml benzene, the organic layers were combined and evaporated *in vacuo*. The residue was stirred with 150 ml ether and the second crop was obtained by filtration; 5·2 g, m.p. 215-216°C. The total yield was thus 71·2 g (43%). Lit.<sup>17</sup>, m.p. 214-215°C.

5,4'-Dichloro-2-methylaminobenzophenone (IV)

A mixture of 52.8 g III and 200 g dimethyl sulfate was stirred for 5 h at 80°C. The warm mixture was treated with 480 ml ethanol, 20 ml water and 26 g Fe fillings, it was heated to reflux and over 90 min 150 ml hydrochloric acid were added dropwise. The mixture was refluxed for 3 h, filtered while hot, the solid was washed with 60 ml ethanol and the filtrate was poured under stirring into 3 l cold water. It was stirred for 1 h, allowed to stand overnight, the yellow product was filtered, washed with water and dried *in vacuo*; 53 g (95%), m.p. 119-121°C. Lit.<sup>18</sup> (different synthetic method), m.p. 123°C.

#### N-[4-Chloro-2-(4-chlorobenzoyl)phenyl]-N-methylchloroacetamide (V)

A mixture of 28.0 g IV and 500 ml benzene was stirred and treated over 50 min with 18.0 g chloroacetyl chloride at  $10^{\circ}$ C; the cooling was achieved by slow addition of ice (totally 400 g ice added). It was stirred for 90 min, the benzene layer was separated, filtered, washed with 250 ml cold 5% NaOH and water, dried (Na<sub>2</sub>SO<sub>4</sub>) and benzene was partly evaporated. The residue was warmed to 75°C and allowed to crystallize in a refrigerator. The product was filtered, washed with a mixture of benzene and hexane, and dried; 28.5 g, m.p.  $160-161^{\circ}$ C. Evaporation of the mother liquor gave another 2.1 g product, the total yield being 30.6 g (86%). Analytical sample, m.p.  $161-162^{\circ}$ C (benzene-hexane). UV spectrum:  $\lambda_{max}$  263 nm (log  $\varepsilon$  4.26). IR spectrum: 779,

790, 805, 899 (2 adjacent and solitary Ar—H), 1 567, 1 585, 3 070, 3 090 (Ar), 1 645 (ArCOAr'), 1 668 cm<sup>-1</sup> (N—CO). <sup>1</sup>H NMR spectrum:  $\delta$  7.70 (d, J = 8.5 Hz, 2 H, 2,6-H<sub>2</sub> in 4-chlorobenzoyl), 7.20–7.52 (m, 5 H, remaining ArH), 3.90 and 3.70 (ABq, 2 H, COCH<sub>2</sub>Cl), 3.35 and 2.98 (2s, 3 H, NCH<sub>3</sub>). For C<sub>16</sub>H<sub>12</sub>Cl<sub>3</sub>NO<sub>2</sub> (356.6) calculated: 53.89% C, 3.38% H, 29.83% Cl, 3.93% N; found: 53.66% C, 3.35% H, 30.00% Cl, 3.99% N.

#### N-[4-Chloro-2-(4-chlorobenzoyl)phenyl]-N-methylphthalimidoacetamide (VI)

A solution of 22.0 g IV in 100 ml chloroform was treated with 17.5 g phthalimidoacetyl chloride<sup>26-28</sup> and the mixture was refluxed for 8 h. Chloroform was evaporated and the warm residue slowly treated with 120 ml ethanol; crystallization took place and was concluded by standing in a refrigerator. The product was filtered, washed with a 1 : 8 mixture of chloroform and ethanol, finally with 50 ml cold ethanol, and was dried; 34.7 g (95%), m.p.  $180-182^{\circ}$ C. Analytical sample, m.p.  $182-183^{\circ}$ C (ethanol). UV spectrum:  $\lambda_{max}$  263 nm (log  $\varepsilon$  4·28), infl. 238 nm (4·35). IR spectrum: 742, 765, 810, 852 (4 and 2 adjacent and solitary Ar—H), 1 480, 1 567, 1 585, 3 030, 3 060, 3 090 (Ar), 1 680 (ArCOAr', NCOR), 1 715, 1 772 cm<sup>-1</sup> [1,2-C<sub>6</sub>H<sub>4</sub>(CO)<sub>2</sub>N]. <sup>1</sup>H NMR spectrum:  $\delta$  7·30-7·90 (m, 11 H, ArH), 4·41 and 4·04 (ABq,  $J = 13\cdot0$  Hz, 2 H, COCH<sub>2</sub>N), 3·35 and 3·00 (2 s, 3 H, NCH<sub>3</sub>). For C<sub>24</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>4</sub> (467·3) calculated: 61·67% C, 3·45% H, 15·18% Cl, 6·00% N; found: 61·63% C, 3·45% H, 15·21% Cl, 6·02% N.

#### N-[2-(2-Fluorobenzoyl)phenyl]phthalimidoacetamide (VIII)

A solution of 26.6 g 2-amino-2'-fluorobenzophenone<sup>29</sup> in 165 ml chloroform was treated with 27.6 g phthalimidoacetyl chloride<sup>26–28</sup>, the mixture was refluxed with stirring for 6 h, allowed to stand overnight at room temperature, evaporated *in vacuo* and the residue was treated with 200 ml boiling ethanol. Crystallization and processing of the mother liquor gave 43.0 g (86%) *VIII*, m.p. 177–179°C. Analytical sample, m.p. 180–182°C (chloroform–ethanol). UV spectrum:  $\lambda_{max}$  230 nm (log  $\varepsilon$  4.63), 265 nm (4.11), 305 nm (3.68). IR spectrum: 752 (4 adjacent Ar–H), 1 522, 1 710 (RCONHAr), 1 581, 1 610, 3 068, 3 100 (Ar), 1 640 (ArCOAr'), 1 720 [1,2-C<sub>6</sub>H<sub>4</sub>. .(CO)<sub>2</sub>N], 3 280 cm<sup>-1</sup> (NH). <sup>1</sup>H NMR spectrum (C<sup>2</sup>H<sub>3</sub>SOC<sup>2</sup>H<sub>3</sub>):  $\delta$  10.71 (s, 1 H, NH), 7.00 to 8.00 (m, 12 H, ArH), 4.29 (s, 2 H, COCH<sub>2</sub>N). For C<sub>23</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>4</sub> (402.4) calculated: 68.65% C, 3.76% H, 4.72% F, 6.96% N; found: 68.38% C, 3.78% H, 4.69% F, 6.86% N.

#### 7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one (II)

A) A mixture of 12.0 g V, 11.0 g hexamethylenetetramine, 150 ml methanol and 15 ml water was stirred and refluxed for 22 h, it was filtered while hot and the filtrate was allowed to crystallize; 10.0 g (94%), m.p. 161–162°C (aqueous ethanol), UV spectrum:  $\lambda_{max}$  317 nm (log  $\varepsilon$  3.41), infl. 253 nm (4.30). IR spectrum: 745, 822, 835, 890 (4 and 2 adjacent and solitary Ar—H), 1482, 1 560, 1 590 (Ar), 1 608 (C=N in conjugation), 1 675, 1 690 cm<sup>-1</sup> (N—CO). <sup>1</sup>H NMR spectrum:  $\delta$  7.30–7.70 (m, 6 H, ArH), 7.20 (d, J = 2.5 Hz, 1 H, 6-H), 4.80 and 3.75 (ABq, J = 13.0 Hz, 1 + 1 H, 3,3-H<sub>2</sub>), 3.38 (s, 3 H, NCH<sub>3</sub>). For C<sub>16</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>2</sub>O (319.2) calculated: 60.20% C, 3.79% H, 22.22% Cl, 8.78% N; found: 59.96% C, 3.86% H, 22.42% Cl, 8.91% N. Lit.<sup>8</sup> (different method of synthesis), m.p. 154–156°C.

B) A suspension of 34.0 g VI in 520 ml methanol was treated with a solution of  $4.75 \text{ g } N_2H_4$ in 24 ml water and the mixture was stirred for 3 h at 60°C. After standing overnight the precipitated solid was filtered and combined with the residue, obtained by evaporation of the filtrate *in vacuo*. The solid was suspended in a mixture of 300 ml water and 100 ml NH<sub>4</sub>OH, the suspension was stirred for 30 min at room temperature, the undissolved product was filtered, washed with diluted NH<sub>4</sub>OH and water, and dried; 22.6 g crude product, m.p.  $160-162^{\circ}$ C. Crystallization from aqueous ethanol gave 18.6 g (80%) pure *II*, m.p.  $161-162^{\circ}$ C, identical with the substance, obtained under *A*.

5(2-Fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one (VII)

A suspension of 43.0 g VIII in 910 ml methanol was treated with a solution of  $11.1 \text{ g N}_2\text{H}_4$ in 28 ml water and the mixture was stirred at 60°C for 3 h. Similar processing like in the preceding case gave 25.5 g (94%) homogeneous (TLC) VII, m.p. 180–183°C. Lit.<sup>29</sup>, m.p. 180–181°C (different method of preparation).

The authors thank Drs J. Holubek and E. Svátek, and Mrs A. Hrádková (Physico-chemical department of this institute) for recording and interpretation of the spectra, and Mrs J. Komancová, Mrs V. Šmidová and Mr M. Čech (Analytical department) for carrying out the analyses.

#### REFERENCES

- 1. Babbini M., Gaiardi M., Bartoletti M.: Life Sci. 25, 15 (1979).
- 2. Braestrup C., Albrechtsen R., Squires R. F.: Nature (London) 269, 702 (1977); Chem. Abstr. 88, 45 132 (1978).
- 3. File S. E., Pellow S.: Psychopharmacology 80, 166 (1983).
- 4. Weissman B. A., Cott J., Paul S. M., Skolnick P.: Eur. J. Pharmacol. 90, 149 (1983).
- 5. File S. E., Green A. R., Nutt D. J., Vincent N. D.: Psychopharmacology 82, 199 (1984).
- 6. Schoemaker H., Boles R. G., Horst W. D., Yamamura H. J.: J. Pharmacol. Exp. Ther. 225, 61 (1983).
- 7. Marangos P. J., Patel J., Boulenger J. P., Clark-Rosenberg R.: Mol. Pharmacol. 22, 26 (1982).
- Sternbach L. H., Fryer R. I., Metlesics W., Recder E., Sach G., Saucy G., Stempel A.: J. Org. Chem. 27, 3 788 (1962).
- Reeder E., Sternbach L. H. (Hoffmann-La Roche Inc.): U.S. 3 136 815 (Swiss Appl. 02.12.60); Chem. Abstr. 61, 9 515 (1964).
- Reeder E., Sternbach L. H. (Hoffmann-La Roche Inc.): U.S. 3 270 053 (Swiss Appl. 02.12.60); Chem. Abstr. 66, 28 808 (1967).
- Reeder E., Sternbach L. H. (Hoffmann-La Roche Inc.): U.S. 3 344 183 (Swiss Appl. 02.12.60); Chem. Abstr. 68, 95 869 (1968).
- Reeder E., Sternbach L. H. (Hoffmann-La Roche Inc.): U.S. 3 402 171 (Swiss Appl. 02.12.60); Chem. Abstr. 70, 37 850 (1969).
- Yamamoto H., Inaba S., Kume Y., Izumi T., Hirohashi T., Yamamoto M., Ishizumi K., Maruyama I., Akatsu M., Mori K. (Sumitomo Chemical Co., Ltd.): Ger. Offen. 2 017 060 (Japan. Appl. 18.04.69-03.07.69); Chem. Abstr. 74, 22 904 (1971).
- 14. Von Brachel H., Graewinger O. (Cassella Farbwerke Mainkur A.-G.): Ger. Offen. 1 942 743 (Appl. 22.08.69); Chem. Abstr. 74, 100 116 (1971).
- Aki O., Nakagawa Y., Shirakawa K., Yamamoto M. (Takeda Chemical Industries, Ltd.): Japan. 73/21 114 (Appl. 21.10.70); Chem. Abstr. 79, 105 306 (1973).
- Mndzhoyan A. L., Papayan G. L., Bagoyan M. A.: Izv. Akad. Nauk Arm. SSR, Khim. Nauki 16, 359 (1963); Chem. Abstr. 60, 11 933 (1964).
- 17. Davis R. B., Pizzini L. C.: J. Org. Chem. 25, 1 884 (1960).
- 18. Mouzin G., Cousse H., Autin J.-M.: Synthesis 1981, 448.
- Lugenheim W., Heidrich H. J.: Ger. (East) 69 134 (Appl. 20.03.68); Chem. Abstr. 72, 90 064 (1970).

- 20. Blaževič N., Kajfež F.: J. Heterocycl. Chem. 7, 1 173 (1970).
- 21. CRC Compagnia di Ricerche Chimiche S. A.: Fr. Demande 2 123 218 (Appl. 29.01.71); Chem. Abstr. 78, 97 727 (1971).
- 22. Podešva C. (Delmar Chemicals Ltd.): Neth. Appl. 65/446 (Brit. Appl. 14.01.64 and 07.04.64); Chem. Abstr. 64, 5 120 (1966).
- 23. Vejdělek Z., Rajšner M., Dlabač A., Ryska M., Holubek J., Svátek E., Protiva M.: This Journal 45, 3 593 (1980).
- 24. Vejdělek Z., Protiva M.: This Journai 48, 1 477 (1983).
- 25. Polívka Z., Holubek J., Svátek E., Metyš J., Protiva M.: This Journal 49, 621 (1084).
- Balenović K., Bregant N., Cerar D., Tkalčic M.: J. Org. Chem. 16, 1 308 (1951); Chem. Abstr. 46, 3 005 (1952).
- 27. Foye W. O., Lange W. E.: J. Amer. Pharm. Assoc. 45, 742 (1956).
- 28. King F. R., Clark-Lewis J. W., Wade R., Swindin W. A.: J. Chem. Soc. 1957, 873.
- Keller O., Steiger N., Sternbach L. H. (Hoffmann-La Roche Inc.): U. S. 3 203 990 (Appl. 20.04.61 and 21.03.62); Chem. Abstr. 64, 3 576 (1966).
- Podešva C., Kohan G. (Delmar Chemicals Ltd.); Can. 871 117 (Appl. 09.09.67); Chem. Abstr. 75, 88 346 (1971).

Translated by the author (M. P.).